another new "glitazone" for type 2 diabetes, Actos (pioglitazone)

August 1999

You'll soon see another new "glitazone" for type 2 diabetes, Actos (pioglitazone)...co-marketed by Lilly and Takeda.

This is the third one...after Avandia (rosiglitazone) and Rezulin (troglitazone).

All three lower blood glucose by improving insulin sensitivity.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

spironolactone (Aldactone) is beneficial for heart failure has been all over the press
Diabetes another new "glitazone" for type 2 diabetes, Actos (pioglitazone)
Dermatology Some commonly-used drugs can cause hair loss
Dermatology starting to prescribe ivermectin for scabies
Gastroenterology an alternative to Rowasa (mesalamine, 5-ASA) suppositories
Gastroenterology Marinol (dronabinol) from Schedule II to Schedule III
Angina first national guidelines for treating chronic stable angina
Renal & Urology new concerns about using Viagra (sildenafil) in patients taking HIV protease inhibitors
Renal & Urology Dietary supplements containing L-arginine are now being promoted for sexual dysfunction
new health claims for some whole grain foods
potential interactions with HERBS in patients on digoxin
Infectious Diseases Norvir (ritonavir) 100 mg capsules are back
Infectious Diseases just two doses of nevirapine (Viramune) can reduce the risk of transmitting HIV
Pediatrics stop giving RotaShield, the new rotavirus vaccine for diarrhea
Pediatrics reduce or eliminate thimerosal as a preservative in pediatric vaccines
Medicare prescription drug benefit would mean significant changes for pharmacists
Practice Relenza (zanamivir), a new INHALED antiviral to reduce flu symptoms
Practice Summer CE Booklet